Pharmaxis

Boehringer Ingelheim initiates phase IIa study of liver disease NASH compound

Tuesday, August 29, 2017

Boehringer Ingelheim and pharmaceutical company Pharmaxis announce that Boehringer Ingelheim has initiated a European and North American phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015. The compound is an oral inhibitor of amine oxidase, copper containing 3 (AOC3), and works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes underlying NASH.

[Read More]